Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 5/20 | 0.40 |
| ▸ | RORC | P51449 | 7/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600860 | 0.90 | F11 (0.41) | ACEXIAPMTNR1BF11 | |
| SCHEMBL3610934 | 0.86 | GHSR (0.43) | ACEXIAPRORCGHSRF11 | |
| SCHEMBL3607627 | 0.86 | ACE (0.47) | ACEXIAPRORCMTNR1B | |
| SCHEMBL3607354 | 0.85 | ACE (0.46) | ACEXIAPRORCMTNR1B | |
| SCHEMBL3608895 | 0.84 | XIAP (0.40) | ACEXIAPRORCF11 | |
| SCHEMBL3612584 | 0.83 | XIAP (0.42) | ACEXIAPRORCF11 | |
| SCHEMBL3608946 | 0.80 | F11 (0.38) | XIAPRORCF11 | |
| SCHEMBL3617469 | 0.78 | ACE (0.43) | ACEXIAPRORCMTNR1BADRB2 | |
| SCHEMBL3604048 | 0.78 | XIAP (0.49) | ACEXIAPMTNR1B | |
| SCHEMBL3604075 | 0.76 | RORC (0.38) | RORCMTNR1BADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | ACE 166/4885XIAP 934/4885RORC 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.